Publicaciones en las que colabora con Andrés Cervantes Ruiperez (7)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2014

  1. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

    European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505

2013

  1. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417

2011

  1. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

    Journal of Clinical Oncology, Vol. 29, Núm. 28, pp. 3783-3790

2005

  1. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

    Journal of Clinical Oncology, Vol. 23, Núm. 34, pp. 8636-8645